Tenecteplase: expanding horizons in thrombolytic therapy across various clinical indications

Abstract

Intravenous thrombolytics remain the mainstay of treatment for ischaemic stroke and retain importance for selected patients with ST-elevation myocardial infarction and pulmonary embolism. Pharmacological and practical advantages of the fibrinolytic tenecteplase have recently led to a widespread shift in ischaemic stroke management. Meta-analysis of randomised trials demonstrated superiority of tenecteplase over alteplase in achieving excellent functional outcome after stroke (no disability). Trials have also extended the time window for thrombolytics in stroke to 24 hours, provided imaging demonstrates salvageable brain tissue. Although endovascular therapy is the most effective treatment for large vessel occlusion stroke, access remains limited to major metropolitan centres in developed nations. Trials suggest that thrombolytics add value, even in patients receiving endovascular therapy, and for many patients globally, intravenous thrombolytics are the only accessible reperfusion treatment. Tenecteplase is established as the preferred thrombolytic for selected patients with ST-elevation myocardial infarction, generally reserved for patients who cannot rapidly access percutaneous intervention following first medical contact. Notably, the dose used is twice that for stroke. Pre-hospital delivery of tenecteplase by paramedics is an important strategy in rural and remote areas. While patients with high-risk pulmonary embolism benefit from systemic thrombolysis, adjunctive tenecteplase in intermediate-risk pulmonary embolism has been associated with increased risk of major bleeding and haemorrhagic stroke. The practical advantages of bolus administration and having a single thrombolytic on formulary for all relevant indications have positioned tenecteplase as the leading thrombolytic agent in current practice. This review discusses the current evidence and treatment guidelines in this rapidly evolving field.

Keywords: Myocardial Infarction; Pulmonary Embolism; Stroke.